Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

12-Week Wearable-Monitored Workplace Exercise Program for Office Workers

6. November 2026 aktualisiert von: Mahidol University

Effects of a 12-Week Wearable-Monitored Workplace Exercise Program on Physical Performance, Cortical Activity, and Proteomic Profiles in Sedentary Office Workers: A Randomized Controlled Trial

This study aims to investigate the effects of a 12-week wearable-monitored workplace exercise program on physical performance, brain activity, and biological markers in office workers.

Prolonged sitting is common among office workers and may negatively affect physical health and well-being. This study will examine whether incorporating regular, technology-assisted exercise breaks into the workday can improve physical performance and produce measurable changes in brain activity and proteins found in blood and sweat.

A total of 78 Thai office workers aged 20-59 years will participate in this study. Participants will be classified according to their habitual physical activity levels into active and sedentary office workers. The 26 active office workers will continue their usual physical activity habits and serve as an active control group. The 52 sedentary office workers will be randomly allocated into two groups: a self-monitoring control group (26 participants) and an experimental group (26 participants).

The self-monitoring control group will receive educational information about the health benefits of reducing prolonged sitting and will use a logbook to monitor their sitting behaviors while maintaining their usual daily routines. The experimental group will participate in a 12-week wearable-monitored workplace exercise program using an intelligent wearable device and a gamified smartphone application. The system provides exercise prompts, real-time feedback, and personalized guidance to encourage participants to perform short exercise sessions during their workday, with a target of at least 150 minutes of exercise per week.

All participants will undergo assessments before and after the intervention. These assessments will evaluate physical performance, muscle strength, movement characteristics, cortical excitability and inhibition using transcranial magnetic stimulation (TMS), and biological markers obtained from blood and sweat samples. Additional assessments will include body composition, physical activity levels, musculoskeletal discomfort, and the usability and acceptability of the exercise system.

The study will compare changes in these measurements among the three groups to determine the effects of the wearable-monitored workplace exercise program and explore its potential benefits for improving physical performance, neurological function, and exercise-related biological responses in office workers.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

78

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

20 Jahre bis 59 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Male or female Thai adults aged 20 to 59 years.
  • Employed full-time (>35 hours/week or ≥4 days/week) in desk-based roles, defined as sitting for ≥50% of working hours.

Exclusion Criteria:

  • Severe physical abnormalities, such as muscle weakness, limited joint mobility, or numbness, that may affect data collection.
  • History of vestibular system disorders, such as Meniere's disease or benign paroxysmal positional vertigo (BPPV).
  • History of neurological disorders, such as ischemic or hemorrhagic stroke.
  • History of lower extremity surgery, such as hip replacement.
  • Inability to read and complete questionnaires or undergo the required testing, including inability to follow standard testing procedures and instructions.
  • Severe visual or hearing impairments that prevent participants from following standard testing procedures or instructions.
  • Anticipated extended absence (>2 weeks) or relocation during the 12-week intervention period.
  • Contraindications to transcranial magnetic stimulation (TMS), including:

Metallic implants, stents, or pacemakers in any part of the body. History of epilepsy or seizure disorders. History of unexplained fainting. History of traumatic brain injury or previous brain trauma.

- Contraindications to sauna bathing, including: Cardiovascular conditions, such as myocardial ischemia, congestive heart failure, cardiac arrhythmias, uncontrolled hypertension (systolic blood pressure >160 mmHg), or resting tachycardia (>100 beats/minute).

History of dermatological conditions, such as psoriasis. History of unexplained chest pain. Pregnancy.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Active Control Group

Participants are physically active office workers who already meet the recommended physical activity levels. They will maintain their habitual physical activity and usual daily routines throughout the 12-week study period without receiving a specific study exercise intervention.

Aktiver Komparator: Self-Monitoring Control Group

Sedentary office workers will receive an educational session about the health benefits of reducing and interrupting prolonged sitting. They will use a sitting diary or logbook to monitor their sedentary behavior while maintaining their usual daily routines throughout the 12-week study period.

An educational session providing information about the health benefits of reducing and interrupting prolonged sitting, accompanied by a sitting diary or logbook for monitoring sedentary behavior throughout the 12-week study period.

Experimental: Wearable-Monitored Exercise Group

Sedentary office workers will participate in a 12-week wearable-monitored workplace exercise program using the Intelligent Health Promotion Service System (IHPSS). The system integrates wearable surface electromyography (sEMG) sensors, a six-axis inertial measurement unit (IMU), and a gamified smartphone application to provide physiological feedback, exercise prompts, and personalized guidance. Participants will perform 5-minute exercise sessions following approximately every 60 minutes of work, targeting at least 150 minutes of exercise per week. Exercise performance will be monitored and adjusted according to movement quality and individual performance.

A 12-week workplace exercise intervention using the Intelligent Health Promotion Service System (IHPSS), an integrated platform combining wearable surface electromyography (sEMG) sensors, a six-axis inertial measurement unit (IMU), and a gamified smartphone application. Participants receive automated auditory and haptic notifications after approximately every 60 minutes of work to perform 5-minute exercise sessions. The daily schedule is repeated for approximately 6-8 hours per day, 4-5 days per week, targeting at least 150 minutes of exercise per week. The system provides real-time muscle activation feedback, movement monitoring, personalized exercise guidance, and performance-based progression.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Resting and Active Motor Thresholds (RMT and AMT) Copy
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Resting motor threshold (RMT) and active motor threshold (AMT) are assessed using transcranial magnetic stimulation (TMS) and recorded as the percentage of maximum stimulator output required to elicit a motor-evoked potential (MEP). RMT is measured during muscle relaxation, while AMT is measured during a 10-20% maximum voluntary contraction.

Baseline (Week 0) and post-intervention (Week 13)
Cortical Silent Period (CSP)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Cortical silent period duration is measured in milliseconds using TMS during sustained muscle contraction. CSP is determined from the interval between the end of the MEP response and the recovery of rectified electromyographic activity to the predefined baseline level.

Baseline (Week 0) and post-intervention (Week 13)
Short-Interval Intracortical Inhibition (SICI) and Intracortical Facilitation (ICF)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Intracortical inhibition and facilitation are assessed using paired-pulse TMS. The ratio of conditioned to unconditioned MEP amplitudes is calculated. SICI is measured at interstimulus intervals of 1, 2, 3, and 5 ms, while ICF is measured at 8, 10, 12, and 15 ms.

Baseline (Week 0) and post-intervention (Week 13)
Motor-Evoked Potential Input/Output Curve
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13).

Corticospinal excitability is assessed by recording MEP amplitudes across TMS stimulus intensities ranging from 90% to 150% of resting motor threshold in 10% increments. Mean peak-to-peak MEP amplitudes are calculated and fitted using a Boltzmann sigmoid function to estimate the plateau amplitude.

Baseline (Week 0) and post-intervention (Week 13).
Plasma and Sweat Extracellular Vesicle Concentration
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13).

Extracellular vesicles isolated from plasma and sweat samples are quantified using nanoparticle tracking analysis (NTA). Vesicle concentration is reported as particles per milliliter (particles/mL).

Baseline (Week 0) and post-intervention (Week 13).
Plasma and Sweat Extracellular Vesicle Size Distribution
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Extracellular vesicle size distribution in plasma and sweat samples is assessed using nanoparticle tracking analysis. The modal vesicle diameter is reported in nanometers, together with the proportion of particles within the 30-150 nm size range.

Baseline (Week 0) and post-intervention (Week 13)
Proteomic Cargo of Plasma and Sweat Extracellular Vesicles
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Protein cargo in plasma and sweat extracellular vesicles is characterized using high-throughput mass spectrometry. Protein profiles are reported as relative protein abundance or presence/absence. Protein identification and functional interpretation are performed using the UniProt human proteome and STRING protein-protein interaction and pathway analyses.

Baseline (Week 0) and post-intervention (Week 13)
Quadriceps Isokinetic Strength
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Quadriceps muscle strength is assessed as peak torque during concentric knee extension at angular velocities of 60, 180, and 300 degrees per second. The highest torque across maximal repetitions at each speed is recorded in Newton-meters (Nm).

Baseline (Week 0) and post-intervention (Week 13)
Shoulder Isokinetic Strength
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Shoulder muscle strength is assessed as peak torque during concentric shoulder through a range of motion of 0-150 degrees at angular velocities of 60 and 120 degrees per second. Peak torque is reported in Newton-meters (Nm).

Baseline (Week 0) and post-intervention (Week 13)
Isometric Handgrip Strength
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Maximum voluntary isometric handgrip force of the dominant hand is measured. The highest value from three trials is recorded in kilograms (kg) or converted to Newtons (N).

Baseline (Week 0) and post-intervention (Week 13)
Time to Peak Hand Velocity
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Hand movement cycles are identified using hand-marker trajectories. Peak resultant hand velocity is determined within each movement cycle, and the time at which peak velocity occurs is expressed as a percentage of the normalized movement cycle (0-100%).

Baseline (Week 0) and post-intervention (Week 13)
Craniovertebral Angle (CVA)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Craniovertebral angle is measured in degrees in the sagittal plane between a horizontal line passing through the C7 vertebral marker and a line connecting the C7 marker to the tragus marker.

Baseline (Week 0) and post-intervention (Week 13)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Body Fat Percentage
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Body fat percentage is assessed using bioelectrical impedance analysis (BIA). The proportion of total body mass consisting of fat is recorded as a percentage (%).

Baseline (Week 0) and post-intervention (Week 13)
Skeletal Muscle Mass
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Skeletal muscle mass is assessed using bioelectrical impedance analysis (BIA). The estimated mass of skeletal muscles is recorded in kilograms (kg).

Baseline (Week 0) and post-intervention (Week 13)
Fat-Free Mass
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Fat-free mass is assessed using bioelectrical impedance analysis (BIA). The estimated mass of body components excluding fat is recorded in kilograms (kg).

Baseline (Week 0) and post-intervention (Week 13)
Physical Activity Level (International Physical Activity Questionnaire)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Physical activity is assessed using the International Physical Activity Questionnaire (IPAQ). Total physical activity is calculated in metabolic equivalent minutes per week (MET-min/week) according to the IPAQ scoring protocol. The results are used to confirm participant classification into active and sedentary groups.

Baseline (Week 0) and post-intervention (Week 13)
Musculoskeletal Discomfort (Nordic Musculoskeletal Questionnaire)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Musculoskeletal discomfort is assessed using the Nordic Musculoskeletal Questionnaire (NMQ). Participants report musculoskeletal problems across nine body regions during the preceding seven days. Point prevalence is calculated as the number of participants reporting problems divided by the total number of participants, expressed as a percentage.

Baseline (Week 0) and post-intervention (Week 13)
Ergonomic Risk Assessment (Rapid Upper Limb Assessment)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13)

Ergonomic risk is evaluated using the Rapid Upper Limb Assessment (RULA). Postures of the upper arms, lower arms, wrists, neck, trunk, and legs are assessed together with muscle-use and force scores to calculate a grand score ranging from 1 to 7.

Baseline (Week 0) and post-intervention (Week 13)
Musculoskeletal Discomfort Severity (Cornell Musculoskeletal Discomfort Questionnaire)
Zeitfenster: Baseline (Week 0) and post-intervention (Week 13).

Musculoskeletal discomfort severity is assessed using the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ). Scores are calculated for each body region by multiplying discomfort frequency, severity, and work interference. Scores range from 0 to 90 per body region.

Baseline (Week 0) and post-intervention (Week 13).
Global Rating of Change
Zeitfenster: Post-intervention (Week 13)

Participants' perceived overall progress is assessed using the Global Rating of Change (GRoC) scale, ranging from -7 (a very great deal worse) to +7 (a very great deal better), with 0 indicating no change.

Post-intervention (Week 13)
System Usability (System Usability Scale)
Zeitfenster: Post-intervention (Week 13)

Usability of the wearable-monitored exercise system is evaluated using the 10-item System Usability Scale (SUS). The total score ranges from 0 to 100, with higher scores indicating better perceived system usability. This assessment is administered to participants in the experimental group.

Post-intervention (Week 13)
Intrinsic Motivation Inventory
Zeitfenster: Post-intervention (Week 13)

Intrinsic motivation is assessed using the Intrinsic Motivation Inventory (IMI), evaluating four dimensions: interest/enjoyment, perceived choice, perceived competence, and pressure/tension. Responses are recorded using a 7-point Likert scale. Negatively worded items are reverse-scored, and the subscale score is calculated as the mean of its items. Scores range from 1 to 7, with higher scores indicating greater perceived autonomy and choice (a more favorable outcome).

Post-intervention (Week 13)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

2. November 2026

Primärer Abschluss (Geschätzt)

28. Oktober 2027

Studienabschluss (Geschätzt)

28. Oktober 2027

Studienanmeldedaten

Zuerst eingereicht

1. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. November 2026

Zuerst gepostet (Tatsächlich)

9. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • MU-MOU 2026/462.2910

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren